Last reviewed · How we verify
Combizym + Bifidobacteri
Combizym + Bifidobacteri is a combination product that provides digestive enzymes and beneficial bifidobacteria to improve gastrointestinal function and restore healthy gut microbiota.
Combizym + Bifidobacteri is a combination product that provides digestive enzymes and beneficial bifidobacteria to improve gastrointestinal function and restore healthy gut microbiota. Used for Digestive enzyme deficiency and gastrointestinal dysfunction, Dysbiosis and microbiota imbalance.
At a glance
| Generic name | Combizym + Bifidobacteri |
|---|---|
| Also known as | Combizym(Oryz-Aspergillus Enzyme And Pancreatin Tablet), (produced by Nordmark Arzneimittel GmbH & Co. KG), Bifidobacteri(Live Combined Bifidobacterium，Lactobac and Enterococcus Capsules), (produced by Shanghai XinYi Company) |
| Sponsor | RenJi Hospital |
| Drug class | Enzyme and probiotic combination |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Combizym supplies pancreatic enzymes (amylase, protease, lipase) to aid digestion of carbohydrates, proteins, and fats. Bifidobacteria are beneficial probiotics that colonize the intestinal tract, promote healthy microbiota balance, and support digestive and immune function. Together, they work to enhance nutrient absorption and gastrointestinal health.
Approved indications
- Digestive enzyme deficiency and gastrointestinal dysfunction
- Dysbiosis and microbiota imbalance
Common side effects
- Gastrointestinal upset
- Mild abdominal discomfort
- Allergic reactions (rare)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |